ST Pharm Co Ltd (237690)

Currency in KRW
106,700
-3,500(-3.18%)
Closed·
237690 is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
102,500107,000
52 wk Range
84,100172,100
Key Statistics
Bid/Ask
106,600.00 / 106,700.00
Prev. Close
106,700
Open
106,000
Day's Range
102,500-107,000
52 wk Range
84,100-172,100
Volume
197.46K
Average Volume (3m)
162.52K
1-Year Change
15.1025%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
237690 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
180,000
Upside
+68.70%
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with high price volatility

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy

Analyst Ratings

10 Buy
0 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 180,000
(+68.70% Upside)

Earnings

Latest Release
Aug 14, 2026
EPS / Forecast
-- / --
Revenue / Forecast
108.5B / 99.41B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 3,312.63%
Dividend Yield
0.45%
Industry Median 1.02%
Annualized payout
500.00
Paid annually
5-Years Growth
-
Growth Streak

237690 Income Statement

Compare 237690 to Peers and Sector

Metrics to compare
237690
Peers
Sector
Relationship
P/E Ratio
31.7x11.3x−0.4x
PEG Ratio
0.260.060.00
Price/Book
3.6x0.9x2.6x
Price / LTM Sales
6.3x0.7x3.1x
Upside (Analyst Target)
78.1%52.4%49.3%
Fair Value Upside
Unlock23.2%6.7%Unlock

ST Pharm Co.,Ltd., provides manufacturing services for active pharmaceutical ingredient and intermediate. The company offers small molecule and generics, an ingredient for treating viral infections; oligonucleotide based products, such as siRNA/microRNA, antisense, aptamer, decoys, and other novel oligos; monomer; and mRNA for vaccines and therapeutics. It also offers pre-clinical and bioanalytical research and development solutions. The company was formerly known as Samchully Pharmaceutical Company., Ltd. ST Pharm Co. Ltd. was founded in 1983 and is headquartered in Siheung-si, South Korea.

Employees
655

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
1.52M7.27%161.96B
Other Institutional Investors
8.88M42.55%947.74B
Public Companies & Retail Investors
10.48M50.18%1.12T
Total
20.88M100.00%2.23T

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Dong-A Socio Holdings Co., Ltd.29.20%6,096,552650,502,098
National Pension Service6.04%1,259,923134,433,784

People Also Watch

501,000
128940
-7.22%
84,400
326030
-2.31%
83,300
000100
-1.19%
32,500
214150
-2.69%
73,000
064400
+0.97%

FAQ

What Is the ST Pharm (237690) Stock Price Today?

The ST Pharm stock price today is 106,700 KRW.

What Stock Exchange Does ST Pharm Trade On?

ST Pharm is listed and trades on the KOSDAQ.

What Is the Stock Symbol for ST Pharm?

The stock symbol for ST Pharm is "237690."

Does ST Pharm Pay Dividends? What’s The Current Dividend Yield?

The ST Pharm dividend yield is 0.47%.

What Is the ST Pharm Market Cap?

As of today, ST Pharm market cap is 2.23T KRW.

What Is ST Pharm's Earnings Per Share (TTM)?

The ST Pharm EPS (TTM) is 3,313.

When Is the Next ST Pharm Earnings Date?

ST Pharm will release its next earnings report on Oct 29, 2026.

From a Technical Analysis Perspective, Is 237690 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has ST Pharm Stock Split?

ST Pharm has split 0 times.

How Many Employees Does ST Pharm Have?

ST Pharm has 655 employees.

What is the current trading status of ST Pharm (237690)?

As of Aug 25, 2026, ST Pharm (237690) is trading at a price of 106,700 KRW, with a previous close of 106,700 KRW. The stock has fluctuated within a day range of 102,500 KRW to 107,000 KRW, while its 52-week range spans from 84,100 KRW to 172,100 KRW.

What Is ST Pharm (237690) Price Target According to Analysts?

The average 12-month price target for ST Pharm is 180,000 KRW, with a high estimate of 210000 KRW and a low estimate of 140000 KRW. 10 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +68.70% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.